Dupilumab significantly improves the day-to-day symptom burden in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

The following is a summary of “Real-world effectiveness of dupilumab in a European cohort of CRSwNP (CHRINOSOR),” published in the October 2024 issue of Allergy and Immunology by Seys et al. Pivotal ...

Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero’s rating is based on ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

THOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line ...

Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP –– Commenced startup for a Phase 2 clinical trial in ...

The following is a summary of “Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP,” published in the August 2024 issue of Allergy and Immunology by Bachert et al.

Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps ...

Its leading drug program is UPB-101. It is in three Phase 2 trials. They are for treating severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease ...